Accession Number

Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed)

DrugDrug Description
LErafAONIntended for the treatment of various forms of cancer.
AGRO100Investigated for use/treatment in cancer/tumors (unspecified), kidney cancer, leukemia (myeloid), and pancreatic cancer.
Egaptivon pegolPlatelet aggregation, thrombosis and acute coronary syndromes
MipomersenAn oligonucleotide drug used for the treatment of homozygous familial hypercholesterolemia.
CPG 10101Investigated for use/treatment in hepatitis (viral, C) and viral infection.
TrabedersenInvestigated for use/treatment in brain cancer, colorectal cancer, melanoma, and pancreatic cancer.
AlicaforsenInvestigated for use/treatment in crohn's disease and ulcerative colitis.
PegnivacoginInvestigated for use/treatment in thrombosis, coronary artery disease, and vascular diseases.
AprinocarsenInvestigated for use/treatment in lung cancer.
FomivirsenIndicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS), when other therapy has been ineffective or is considered unsuitable [FDA Label, L1428].
PegaptanibA selective vascular endothelial growth factor (VEGF) antagonist used for the treatment of neovascular (wet) age-related macular degeneration.
ISS-1018Investigated for use/treatment in colorectal cancer, hepatitis (viral, B), and lymphoma (non-hodgkin's). ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent...
NF-kappaB DecoyInvestigated for use/treatment in atopic dermatitis, inflammatory disorders (unspecified), and skin infections/disorders.
GTI-2040GTI-2040 is under investigation in clinical trial NCT00084643 (GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors).
ARC-19499ARC-19499 is under investigation in clinical trial NCT01191372 (First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients).
EteplirsenAn antisense oligonucleotide used to treat Duchenne muscular dystrophy (DMD) only in patients who are confirmed to have a specific type of mutation.
Lexaptepid pegolLexaptepid pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases, End Stage Renal Disease, and Anemia of Chronic Disease.
OblimersenNot Annotated
InotersenAn antisense oligonucleotide used to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis.
RadavirsenRadavirsen is under investigation in clinical trial NCT01375985 (Safety Study of Single Administration Intravenous Treatment for Influenza).
Adenylyl-(3'-5')-uridine 3'-monophosphateNot Available
GivosiranA 5-aminolevulinic acid synthase-directed small interfering RNA (siRNA) used in the prophylaxis of acute hepatic porphyria.
ViltolarsenAn antisense phosphorodiamidate morpholino oligonucleotide specific for exon 53 of the human DMD gene that is capable of inducing exon 53 skipping to produce a functional truncated dystrophin protein in Duchenne muscular dystrophy patients with specific underlying mutations.
ISIS 2503ISIS 2503 is under investigation in clinical trial NCT00004193 (ISIS 2503 in Treating Patients With Metastatic And/or Locally Recurrent Colorectal Cancer).
ISIS 104838ISIS 104838 is under investigation in clinical trial NCT00048321 (ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis).
CasimersenAn antisense phosphorodiamidate morpholino oligonucleotide used to treat Duchenne muscular dystrophy patients with mutations amenable to exon 45 skipping.
Drugs & Drug Targets
LErafAONRAF proto-oncogene serine/threonine-protein kinasetarget
AGRO100NF-kappa-B essential modulatortarget
Egaptivon pegolvon Willebrand factortarget
Egaptivon pegolPlatelet glycoprotein Ib alpha chaintarget
MipomersenmRNA of ApoB-100target
CPG 10101Toll-like receptor 9target
TrabedersenTransforming growth factor beta-2target
AprinocarsenProtein kinase C alpha typetarget
Fomivirsen30 kDa immediate-early protein 2target
Fomivirsen45 kDa immediate-early protein 2target
PegaptanibVascular endothelial growth factor Atarget
ISS-1018Toll-like receptor 9target
NF-kappaB DecoyNuclear factor NF-kappa-Btarget
EteplirsenDMD-001 gene (exon 51 target site)target
InotersenTransthyretin mRNAtarget
Adenylyl-(3'-5')-uridine 3'-monophosphateDiphtheria toxintarget
GivosiranALAS1 mRNAtarget
ViltolarsenDMD gene (exon 53 viltolarsen target site)target
CasimersenDMD gene (exon 45 casimersen target site)target
CasimersenCytochrome P450 3A4enzyme
CasimersenCytochrome P450 3A5enzyme
CasimersenCytochrome P450 2C9enzyme
CasimersenCytochrome P450 2C19enzyme